# Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

> **NCT05465031** · PHASE4 · RECRUITING · sponsor: **Silesian Centre for Heart Diseases** · enrollment: 600 (estimated)

## Conditions studied

- Breast Cancer
- Neoplasm, Breast
- Breast Diseases
- Antihypertensive Agents
- Sacubitril/Valsartan
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Molecular Mechanisms of Pharmacological Action
- Heart Failure
- Cardiac Toxicity
- Cancer, Therapy-Related
- Cancer Therapy-Related Cardiac Dysfunction
- Cardiotoxicity

## Interventions

- **DRUG:** Sacubitril-valsartan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05465031
- **Lead sponsor:** Silesian Centre for Heart Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2027-12
- **Final completion:** 2029-02
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465031, "Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05465031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*